A potential new treatment approach for hereditary neurological disorder, the incurable Charcot-Marie-Tooth disease, has been found by researchers. Patients with Charcot-Marie-Tooth disease type 1A harbour an extra copy of the PMP22 gene which leads to the overproduction of the peripheral myelin protein 22 (PMP22), a key component of myelin.